nation
institut
allergi
infecti
diseas
niaid
integr
research
facil
irf
sab
anim
facil
anim
program
accredit
associ
assess
accredit
laboratori
anim
care
intern
studi
protocol
review
approv
sab
niaid
irf
institut
anim
care
use
committe
complianc
applic
feder
regul
govern
protect
anim
research
transchromosom
bovin
product
previous
describ
two
tcbovin
immun
intramuscularli
im
ebovmakona
rgp
zair
variant
novavax
inc
formul
sab
proprietari
adjuv
tcbovin
vaccin
time
wk
interv
antigen
dose
per
anim
first
vaccin
per
anim
plasma
serum
sampl
taken
variou
time
point
andor
vaccin
volum
prevaccin
plasma
collect
studi
tcbovin
use
neg
control
tchigg
bodi
weight
hyperimmun
plasma
per
anim
per
time
point
collect
immun
tcbovin
antiebov
fulli
human
polyclon
antibodi
product
postvaccin
start
plasma
collect
use
autom
plasmapheresi
system
autopheresi
c
model
baxter
healthcar
store
frozen
purif
perform
product
tchigg
tcbovin
plasma
previous
describ
isol
ebola
genbank
access
cultur
method
studi
viru
stock
intern
refer
previous
describ
viru
stock
genotyp
genbank
access
determin
nextgener
sequenc
previous
describ
pseudovirion
neutral
assay
psvna
perform
previous
describ
assay
conduct
use
nonrepl
vesicular
stomat
viru
without
gp
gp
replac
luciferas
pseudotyp
ebov
kikwit
variant
gp
titer
sampl
averag
independ
experi
fluoresc
reduct
neutral
plaqu
reduct
neutral
african
green
monkey
kidney
cell
vero
american
type
tissu
cultur
collect
atcc
manassa
va
maintain
dulbecco
modifi
eagl
medium
dmem
high
glucos
lglutamin
catalog
lonza
walkersvil
md
contain
heatinactiv
fetal
bovin
serum
catalog
milliporesigma
life
scienc
research
danver
cell
seed
use
cellswel
plate
catalog
greiner
bioon
north
america
monro
nc
cellswel
plate
catalog
corn
corn
ny
respect
incub
sampl
lot
thaw
use
immedi
without
heat
inactiv
test
sampl
serial
dilut
dilut
cell
cultur
media
without
ad
fetal
bovin
serum
ebov
makona
isol
dilut
mix
sampl
achiev
final
target
titer
plaqueform
unit
pfu
well
virussampl
mixtur
incub
h
transfer
plate
contain
confluent
vero
cell
incub
h
antiebov
antibodi
catalog
ibt
bioservic
rockvil
md
includ
confirm
assay
perform
plate
fix
buffer
formalin
minut
min
room
temperatur
buffer
formalin
overnight
cell
permeabil
triton
buffer
triton
phosphatebuff
salin
pb
min
room
temperatur
plate
wash
time
block
normal
goat
serum
cell
stain
antiebov
antibodi
mous
us
armi
medic
research
institut
infecti
diseas
frederick
md
wash
stain
fluoresc
label
secondari
antibodi
goat
antimous
catalog
life
technolog
carlsbad
ca
visual
highcont
imag
system
operetta
perkinelm
waltham
valu
determin
dilut
reduct
virusposit
cell
compar
well
contain
viru
antibodi
plaqu
reduct
neutral
test
perform
previous
describ
follow
except
incub
instead
virusserum
inoculum
ad
duplic
well
plate
contain
confluent
vero
cell
dmem
fetal
bovin
sera
penicillinstreptomycin
catalog
thermo
fisher
scientif
enzymelink
immunosorb
assay
elisa
titer
determin
use
human
antiebov
antibodi
gp
nucleoprotein
np
previous
describ
assay
result
consid
valid
sampl
duplic
coeffici
varianc
intern
posit
control
optic
densiti
od
od
unit
recombin
ebov
gp
without
transmembran
protein
catalog
ibt
bioservic
rockvil
md
biotinyl
conjug
yellowgreen
fluoresc
bead
catalog
thermo
scientif
waltham
tcbovin
sera
andor
purifi
igg
subclass
irrelev
tchigg
incub
h
human
monocyt
cell
atcc
ad
concentr
cellswel
incub
approxim
h
cell
fix
analyz
flow
cytometri
phagocyt
score
determin
use
percentag
fluorescein
isothiocyan
fitc
cell
geometr
mean
fluoresc
intens
gmfi
fitc
fitc
cell
fitc
cell
gmfi
fitc
ebov
gpcoupl
bead
gener
describ
antibodymedi
monocyt
phagocytosi
admp
see
tcbovin
sera
andor
purifi
igg
subclass
irrelev
tchigg
incub
ebov
gpcoupl
bead
h
human
neutrophil
freshli
isol
peripher
blood
ad
concentr
cellswel
incub
h
cell
stain
biolegend
catalog
bd
bioscienc
san
jose
ca
catalog
bd
bioscienc
analyz
flow
cytometri
bd
lsr
ii
flow
cytomet
bd
franklin
lake
nj
neutrophil
defin
side
scattera
high
phagocyt
score
determin
use
percentag
fitc
cell
gmfi
fitc
cell
coat
maxisorp
elisa
plate
thermo
scientif
plate
block
bovin
serum
albumin
addit
tchigg
h
human
natur
killer
nk
cell
enrich
peripher
blood
mononuclear
cell
neg
select
specif
antibodi
use
rosettesep
catalog
stemcel
technolog
cambridg
nk
cell
ad
cellswel
presenc
brefeldin
catalog
millipor
sigma
golgistop
catalog
bd
bioscienc
catalog
bd
bioscienc
incub
h
natur
killer
cell
stain
surfac
marker
nk
cell
bd
bioscienc
intracellularli
stain
interferon
ifn
macrophag
inflammatori
protein
mip
bd
bioscienc
cell
analyz
flow
cytometri
bd
lsr
ii
flow
cytomet
bd
bioscienc
data
analyz
use
flowjo
softwar
flowjo
ashland
ebov
rgp
ibt
bioservic
coupl
fluoresc
microspher
luminex
austin
tx
carbodiimid
crosslink
chemistri
use
nhydroxysulfosucciminimid
thermo
fisher
scientif
coupl
bead
incub
antibodi
sampl
mgml
shake
revolut
per
min
overnight
unbound
antibodi
remov
wash
time
pb
tween
specif
subclass
detect
use
phycoerythrinconjug
secondari
antibodi
specif
human
igg
southern
biotech
birmingham
al
h
room
temperatur
shake
mean
fluoresc
intens
determin
acquisit
minimum
bead
bioplex
suspens
array
system
biorad
hercul
ca
proport
human
determin
use
igg
subclass
elisa
previous
describ
steadyst
equilibrium
bind
purifi
tcbovin
igg
monitor
use
proteon
surfac
plasmon
reson
spr
system
biorad
previous
describ
follow
except
sampl
instead
freshli
prepar
igg
prepar
evalu
parallel
antibodi
dissoci
curv
postvaccin
igg
sampl
establish
previous
describ
presenc
assess
tchigg
elisa
method
use
murin
monoclon
antibodi
catalog
enzo
life
scienc
farmingdal
ny
specif
bind
residu
test
sampl
control
blank
coat
well
plate
nonfat
dri
milk
use
block
agent
wash
pb
contain
tween
murin
monoclon
antibodi
ad
well
dilut
per
manufactur
instruct
antimous
igm
horseradish
peroxidas
hrp
dilut
use
detect
antibodi
bound
hrp
activ
detect
ad
substrat
catalog
kpl
od
valu
nm
measur
autom
micropl
reader
model
powerwavex
biotek
instrument
inc
blank
neg
control
od
valu
elisa
method
test
sampl
control
includ
follow
tchigg
sab
biotherapeut
inc
sioux
fall
sd
antithymocyt
globulin
atg
equin
pfizer
new
york
ny
atg
rabbit
thymoglobulin
sanofi
us
bridgewat
nj
human
ivig
flebogamma
dual
inactiv
plu
nanofiltr
grifol
use
neg
control
cetuximab
erbitux
bristolmy
squibb
new
york
ny
use
posit
control
cetuximab
gift
dr
john
lee
sanford
research
sioux
fall
sd
known
contain
fourteen
nhp
male
femal
year
age
randomli
assign
group
earlyintervent
ei
group
n
irrelev
tchigg
control
group
n
infectioncontrol
group
normal
salin
n
target
infect
dose
pfu
pfu
actual
isol
given
im
postinfect
nhp
schedul
receiv
mgkg
irrelev
tchigg
equival
volum
normal
salin
figur
target
dose
administr
schedul
base
upon
neutral
titer
opinion
investig
time
constraint
need
infus
nhp
sedat
biosafeti
level
set
ten
nhp
survivor
ei
n
di
n
group
backchalleng
target
dose
pfu
pfu
actual
dose
isol
given
im
initi
challeng
assess
adapt
immun
figur
twelv
nhp
male
femal
year
age
randomli
assign
group
lateintervent
li
group
n
irrelev
tchigg
control
group
n
salin
control
group
n
target
infect
dose
pfu
pfu
actual
dose
isol
given
im
postinfect
nhp
schedul
receiv
dose
mgkg
irrelev
tchigg
equival
volum
normal
salin
figur
target
dose
administr
schedul
base
upon
result
experi
administr
fourth
dose
could
vari
depend
upon
clinic
statu
anim
nonhuman
primat
serum
chemistri
perform
previous
describ
quantit
polymeras
chain
reaction
pcr
perform
previous
describ
plasma
viru
load
measur
use
bei
resourc
critic
reagent
program
crp
quantit
reversetranscriptionpcr
kit
assay
accord
manufactur
instruct
report
gene
equival
ge
per
sampl
ebov
pcr
sampl
nhp
experi
analyz
escap
mutant
resist
deep
sequenc
analysi
previous
describ
frozen
trizoltr
tissu
homogen
cellfre
fluid
sampl
process
extract
total
rna
use
directzol
zymo
research
irvin
ca
accord
manufactur
protocol
oncolumn
dnase
digest
step
includ
rna
elut
volum
rna
integr
puriti
assay
use
rna
pico
chip
agil
bioanalyz
agil
technolog
santa
clara
ca
rna
mass
determin
fluoresc
detect
use
qubit
broad
rang
rna
kit
life
technolog
rna
sampl
store
use
illumina
rna
access
librari
illumina
san
diego
ca
prepar
illumina
probecaptur
librari
construct
use
input
ng
total
rna
follow
manufactur
protocol
first
second
hybrid
perform
group
individu
librari
use
custom
set
probe
specif
ebov
probe
tile
across
genom
repres
member
filoviru
famili
supplementari
tabl
repres
genom
complet
genom
probe
librari
qualiti
check
use
deoxyribonucl
acid
dna
chip
agil
bioanalyz
librari
pool
group
sequenc
illumina
miseq
use
chemistri
base
pair
pairedend
effector
cell
function
tcbovin
sera
evalu
use
spearman
correl
coeffici
jmp
pro
softwar
sa
institut
cari
nc
r
valu
calcul
use
jmp
heat
map
gener
use
gene
softwar
broad
institut
cambridg
test
fisher
exact
test
determin
similar
random
group
age
weight
test
sex
fisher
exact
test
use
r
open
softwar
r
foundat
vienna
austria
spotfir
version
tibco
softwar
palo
alto
ca
descript
data
tabl
figur
present
result
three
sequenti
gmp
lot
produc
postvaccin
plasma
tcbovin
lot
produc
plasma
third
fourth
vaccin
lot
produc
plasma
sixth
eighth
vaccin
lot
test
antibodi
neutral
andor
titer
ebov
gp
andor
np
per
mg
lot
gp
recombin
viru
makona
wildtyp
viru
makona
wildtyp
viru
elisa
recombin
gpnp
protein
use
differ
collabor
tabl
titer
individu
vaccin
time
point
tcbovin
no
publish
previous
neutral
titer
lot
compar
lot
approxim
time
time
less
respect
contrast
elisa
rgp
elisa
unit
eu
mg
titer
time
differ
lot
elisa
rnp
titer
detect
lot
tabl
postvaccin
tcbovin
sera
lot
irrelev
tchigg
intern
control
antiebov
monoclon
antibodi
posit
control
salin
neg
control
evalu
abil
induc
phagocytosi
monocyt
neutrophil
degranul
nk
cell
vitro
cultur
fluoresc
bead
coat
ebov
rgp
irrelev
tchigg
induc
human
monocyt
neutrophil
admp
antibodymedi
neutrophil
phagocytosi
adnp
activ
nk
cell
measur
express
secret
protein
degranul
background
level
establish
normal
salin
figur
tcbovin
sera
antibodi
antibodi
class
recruit
admp
activ
background
yet
admp
activ
gradual
decreas
subsequ
vaccin
figur
contrast
tcbovin
serum
antibodi
recruit
adnp
activ
background
adnp
gradual
increas
subsequ
vaccin
figur
natur
killer
cell
degranul
demonstr
protein
marker
induc
background
activ
sustain
addit
vaccin
figur
although
similar
level
admp
adnp
activ
figur
b
higher
induct
nk
cell
degranul
figur
monoclon
antibodi
induc
admp
antibodi
induc
adnp
background
figur
b
neither
antiebov
monoclon
antibodi
induc
nk
cell
degranul
background
figur
lot
lot
higher
proport
compar
humanderiv
ivig
respect
proport
less
tabl
titer
ebov
gpspecif
total
igg
subclass
antibodi
isol
bovin
sera
lot
lot
induc
sustain
high
titer
determin
microspherebas
igg
method
figur
contrast
titer
ebov
gpspecif
subclass
antibodi
isol
bovin
sera
time
lower
total
igg
subclass
although
titer
peak
gener
declin
addit
vaccin
figur
fc
fragment
differ
iggspecif
subclass
vari
affin
cellular
fc
receptor
effector
cell
next
determin
whether
induct
multipl
fcmediat
effector
function
eg
admpadnp
cytokin
express
activ
nk
cell
correl
ebovgp
iggspecif
subclass
determin
whether
total
igg
igg
subclass
associ
specif
function
spearman
coeffici
use
determin
correl
admp
activ
signific
posit
associ
total
ebov
gpspecif
igg
suggest
admp
activ
driven
part
antigenspecif
antibodi
titer
figur
e
contrast
neither
adnp
nk
cell
degranulationactiv
strongli
correl
subclass
suggest
extent
induct
function
sole
base
antibodi
titer
determin
whether
abil
antibodi
induc
given
function
associ
induct
function
correl
analys
perform
induct
admp
activ
strongli
correl
function
rs
yet
adnp
activ
nk
cell
degranul
activ
display
moderatetoveri
strong
posit
correl
rs
figur
c
e
steadyst
equilibrium
spr
analysi
use
evalu
total
antiebov
antibodi
avid
lot
lot
homolog
ebov
isol
heterolog
rgp
isol
immobil
histidinetag
protein
gold
sensor
chip
total
antibodi
bind
antibodi
affin
higher
rgp
homolog
ebovmakona
isol
compar
observ
heterolog
ebovmayinga
isol
maximum
reson
unit
valu
total
antigp
bind
antibodi
higher
ebovmayinga
gp
ebovmakona
isol
respect
compar
antibodi
supplementari
figur
avid
antibodi
measur
antibodi
offrat
constant
approxim
higher
ebovmayinga
gp
ebovmakona
isol
compar
antibodi
supplementari
figur
residu
caus
anaphylaxi
human
therefor
presenc
assess
tchigg
use
elisa
method
level
tchigg
similar
human
ivig
antithymoglobulin
equin
rabbit
polyclon
antibodi
control
od
valu
approxim
test
howev
level
monoclon
antibodi
cetuximab
od
valu
approxim
test
higher
supplementari
tabl
evalu
efficaci
nhp
ebov
challeng
experi
conduct
figur
elisa
igg
antibodi
serum
titer
rgp
target
euml
preinfus
limit
quantif
loq
nhp
experi
elisa
rgp
titer
nhp
experi
receiv
ei
infus
postinfect
measur
postinfect
rang
euml
fell
postinfect
rang
euml
figur
supplementari
tabl
elisa
rgp
titer
ei
infus
postinfect
delay
di
infus
initi
postinfect
nhp
experi
infus
initi
measur
andor
postinfect
rang
euml
progress
fell
postinfect
rang
euml
figur
supplementari
tabl
rnp
titer
experi
ei
di
nhp
preinfus
rang
loq
peak
rang
euml
fell
postinfect
rang
loq
euml
supplementari
tabl
elisa
rgp
titer
nhp
receiv
li
infus
initi
postinfect
experi
measur
necropsi
rang
euml
figur
supplementari
tabl
two
nhp
ei
group
surviv
eo
figur
survivor
anim
clinic
symptomat
sporad
viremia
detect
ebov
rna
within
csf
necropsi
nonsurvivor
ei
group
develop
viremia
postinfect
blood
chemistri
abnorm
die
postinfect
accompani
viru
within
csf
necropsi
anim
irrelev
tchigg
salin
control
group
develop
viremia
postinfect
blood
chemistri
abnorm
die
postinfect
viru
detect
csf
anim
necropsi
supplementari
tabl
nonsurvivor
blood
chemistri
necropsi
consist
lethal
ebov
diseas
figur
anim
ei
di
group
surviv
without
clinic
sign
ebov
infect
blood
chemistri
abnorm
eo
serum
csf
anim
ei
group
viremia
geml
geml
postinfect
nhp
receiv
irrelev
tchigg
develop
viremia
postinfect
geml
blood
chemistri
abnorm
succumb
diseas
postinfect
viremia
geml
supplementari
tabl
figur
nonsurvivor
blood
chemistri
necropsi
consist
lethal
ebov
diseas
nhp
li
irrelev
tchigg
normal
salin
group
becam
virem
li
group
die
postinfect
figur
supplementari
tabl
ebov
csf
concentr
necropsi
supplementari
tabl
blood
chemistri
figur
nonsurvivor
consist
lethal
ebov
diseas
anim
succumb
experi
underw
necropsi
find
includ
multifoc
petechia
ventral
bodi
surfac
enlarg
axillari
lymph
node
correspond
arm
viru
inocul
gross
manifest
necropsi
includ
hemorrhag
adren
gland
mucos
hemorrhag
stomach
urinari
bladder
kidney
lesion
rang
vascular
congest
tubular
necrosi
hemorrhag
hemoglobinuria
hemorrhag
intravascular
fibrin
thrombi
note
test
lesion
cerebr
cortex
includ
vascular
congest
intravascular
fibrin
thrombi
find
consist
lesion
previous
found
nhp
lethal
ebov
infect
followup
studi
quantifi
viru
antigen
load
nhp
survivor
nonsurvivor
brain
retina
tissu
treat
conduct
deep
sequenc
ebov
rna
isol
pcr
serum
csf
sampl
experi
indic
resist
due
viral
escap
mutant
purpos
effort
rapidli
develop
antiebov
immunotherapeut
hyperimmun
tcbovin
evalu
characterist
efficaci
number
vitro
vivo
experi
vitro
assay
assess
includ
potenti
use
clinic
set
patient
manag
elisa
assay
research
set
pseudoviru
prntfrna
spr
effector
cell
assay
gmp
product
set
qualiti
controlreleas
specif
igg
subclass
spr
assay
regulatori
set
address
potenti
patientsafeti
issu
assay
clinic
test
one
consist
observ
higher
neutral
titer
total
antiebov
antibodi
avid
assay
regardless
whether
ebov
variant
homolog
heterolog
like
explan
affin
tcbovin
antiebov
antibodi
clone
continu
matur
adapt
immun
respons
success
vaccin
target
ebovmakonaspecif
epitop
ebovconserv
epitop
result
like
indic
tchigg
deriv
plasma
later
vaccin
potent
deriv
earlier
vaccin
therefor
dose
base
upon
result
postproduct
immunogen
assay
lot
correl
futur
anim
model
andor
human
efficaci
observ
also
show
tcbovin
antibodi
similar
level
compar
humanderiv
ivig
caus
humanimmunolog
barrier
xenotransplant
anaphylaxishypersensit
reaction
human
equin
antivenom
cetuximab
administr
red
meat
consumpt
caus
reaction
result
recent
complet
phase
clinic
trial
healthi
adult
antim
cov
indic
well
toler
studi
human
determin
safeti
andor
immunogen
need
tchigg
product
addit
directli
neutral
viral
fusion
andor
entri
host
cell
antibodi
contribut
control
infect
clearanc
viru
fc
domain
via
activ
innat
immun
cell
neutrophil
monocyt
nk
cell
via
phagocytosi
viru
andor
antibodydepend
cellular
cytotox
adcc
infect
cell
exampl
adnp
initi
iggimmun
complex
fc
bind
activ
receptor
share
extracellular
domain
therefor
similar
bind
profil
igg
contrast
admp
driven
iggimmunocomplex
fc
bind
activ
receptor
thu
differenti
bind
igg
antibodi
may
relat
differ
fcreceptor
use
drive
adnp
andor
admp
natur
killer
cell
express
similar
adnp
activ
nk
cell
degranul
express
produc
cytokin
chemokin
induc
adcc
infect
cell
grow
bodi
evid
suggest
adcc
may
contribut
efficaci
monoclon
antibodi
ebov
nk
cell
monocyt
implic
protect
ebov
diseas
nhp
model
demonstr
strongli
activ
class
human
phagocyt
andor
adcceffector
cell
monocyt
neutrophil
nk
cell
vitro
indic
fcdomain
protein
glycosyl
structur
tcbovin
igg
highli
function
strongli
interact
fcrbear
cell
therefor
recruit
innat
immun
effector
cellsact
human
addit
subtyp
potent
activ
adcc
compris
compar
typic
rang
humanderiv
ivig
product
abil
andor
antibodi
induc
multipl
fcdomainmedi
effector
function
term
polyfunction
associ
elit
control
human
immunodefici
infect
polyfunction
may
relev
efficaci
immunotherapeut
ebov
viral
agent
therefor
may
activ
global
effectorcel
respons
human
function
possibl
animalderiv
ivig
nonhuman
fc
region
humanderiv
ivig
proport
less
vivo
result
indic
deliv
ebov
exposur
protect
nhp
death
ill
importantli
infus
dose
well
toler
nhp
even
anim
highli
virem
result
also
indic
lowdos
lowerpot
deliv
ebov
infect
higher
dose
higher
potenc
deliv
ebov
infect
provid
limit
protect
note
nhp
li
group
alreadi
highli
virem
blood
chemistri
abnorm
postinfect
therefor
ebov
infect
advanc
time
tchigg
therapi
initi
nhp
succumb
within
postinfect
treatment
better
surviv
may
obtain
deliv
lower
potenc
postinfect
higher
potenc
postinfect
respect
altern
compress
dose
schedul
could
implement
includ
singl
administr
total
plan
dose
first
treatment
improv
efficaci
howev
although
dose
schedul
may
practic
human
patient
care
scenario
administr
volum
sedat
nhp
set
practic
due
time
logist
constraint
studi
smaller
group
nhp
could
answer
question
addit
possibl
ebov
immunotherapeut
deliv
earli
primari
ebov
infect
prevent
develop
protect
adapt
immun
respons
lack
adapt
immun
respons
indic
death
major
ei
nhp
none
di
nhp
backchalleng
experi
supplementari
tabl
fatal
occur
ei
group
despit
presenc
antiebov
gp
antibodi
backchalleng
histori
transient
antinp
antibodi
postprimari
infect
recoveri
phase
mechan
prevent
adapt
immun
known
conjectur
deliv
infect
bound
mask
epitop
ebov
gp
antigen
also
stimul
innateimmun
effector
cell
via
fc
receptor
bind
caus
releas
immunomodul
cytokin
mask
prevent
andor
b
cell
develop
adequ
protectiveadapt
immun
respons
howev
studi
need
clarifi
mechan
observ
taken
togeth
vitro
vivo
data
suggest
accept
intrinsicsafeti
profil
human
use
efficaci
neutral
viru
vitro
strongli
induc
innat
immun
effector
function
protect
nhp
ebov
diseas
result
suggest
may
effect
treat
humanebov
infect
could
progress
clinic
evalu
respons
platform
new
emerg
infecti
diseas
current
manufactur
process
produc
gmp
tchigg
immun
begin
exist
experiment
plasmid
dna
recombin
protein
wholeviru
vaccin
method
reduc
product
time
consid
investig
method
includ
preprim
tcbovin
vaccin
known
pathogen
interest
primeboost
combin
differ
vaccin
new
adjuv
increas
acceler
immun
respons
genet
engin
improv
adapt
immun
respons
humanantibodi
yield
final
futur
vitro
vivo
studi
compar
antiebov
antibodi
product
anim
andor
human
consid
